Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Researchers from the US recently described a rapid molecular test named WHotLAMP for the detection of SARS-CoV-2 in saliva. WHotLAMP is easy to use, very sensitive at 3.6 viral RNA copies per microliter of saliva, specific, and inexpensive. This study is published on the medRxiv*preprint serve.
A recent study, published in the American Society for Microbiology’s journal, mSphere, evaluated the use of many liquid chalk products as antiseptics against the transmission of highly pathogenic human viruses such as influenza A virus (H1N1), SARS-CoV-2, (IAV), and norovirus in a mouse norovirus (MNV) model. The researchers applied chalk before or after virus inoculum and determined the recovery of infectious virus to mimic its use in the gym setting.
When two St. Louis Blues hockey players were sidelined because of covid-19 just days before this year's NHL playoffs, the team said young defenseman Jake Walman had been vaccinated against the deadly illness. But it was mum about the vaccination status of a more well-known player: star forward David Perron.
A study published in the journal Inflammopharmacology reviewed recent data related to the role of vitamins and minerals in treating COVID-19 patients. The primary goal of the review is to highlight the possible therapeutic role of vitamins A, B, C, D, E and K, and micronutrients as immunity boosters in COVID-19 patients.
The SARS-CoV-2 virus that causes COVID-19 may have the ability to reactivate dormant tuberculosis (TB). In a novel study scientists report in The American Journal of Pathology that infection with a specific coronavirus strain reactivated dormant Mycobacterium tuberculosis (MTB) in mice.
A new study, recently published in the journal Viruses, describes the impressive evidence for the role of antimicrobial peptidse (AMPs) in the treatment of COVID-19.
A new study from the University of Chicago and Scripps Research Institute shows that during the last great pandemic--2009's H1N1 influenza pandemic--people developed strong, effective immune responses to stable, conserved parts of the virus.
A different type of surge may be on the way more than a year into the pandemic - a baby surge.The COVID-19 shutdown initially seemed to hit pause on pregnancy and birth rates, new research from one major hospital system suggests, but that trend is quickly reversing.
A new preprint research paper posted to the bioRxiv* server offers a potential candidate for disinfecting the respiratory tract and mouth during and after exposure to the virus, in the form of proprietary herbal oil named Viruxal.
New research undertaken by researchers in the USA describes two parallel but distinct in vivo approaches for the accelerated discovery of antibodies targeting SARS-CoV-2 spike protein.
As early as the Neolithic period (circa 3900 BC), the domestication of animals likely led to the development of diseases including measles and smallpox. Since then, zoonotic disease has led to other major transnational outbreaks including HIV, Ebola, SARS, MERS, and H1N1 swine flu, among others.
New research by a team of scientists in the USA describes the potential utility of a drug called probenecid, commonly used to treat gout, to treat this devastating viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19.
With data obtained from the Virus Watch study in England and Wales, researchers found that the serial interval of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is broadly similar to estimates from previous studies and there is no evidence that the B.1.1.7 variant is associated with any change.
Researchers have identified specific influenza targets that could be used to better protect Indigenous people from experiencing severe influenza disease through a universal, T cell-based vaccine.
Now, in new research posted to the bioRxiv preprint server, scientists at Novavax, Inc. present a vaccine including recombinant influenza hemagglutinin (HA) antigen along with recombinant SARS-CoV-2 spike protein, with saponin Matrix-M adjuvant. Both have passed independent safety tests in phase 1 trials.
Researchers at Duke University, USA, are looking into the possibility of a combined influenza and COVID-19 vaccine that could be used to simultaneously protect against annual flu strains and the SARS-CoV-2. Preclinical results showed the vaccine protected mice from both SARS-CoV-2 and the flu.
The quick detection of an ultra-rare blood clotting reaction in some Covid-19 vaccine recipients showed the power of a federal warning system for vaccine safety issues, but experts worry that blind spots in the program could hamper detection of other unexpected side effects.
The potential of using this gene manipulation technology as a SARS-CoV-2 inhibitor or prophylactic is investigated in a review recently uploaded to the journal Experimental Biology and Medicine (April 25th, 2021) by Arnab Banerjee and colleagues.
A new treatment is among the first known to reduce the severity of acute respiratory distress syndrome caused by the flu in animals, according to a new study.
Researchers at the University of Helsinki have identified influenza virus peptides that resemble human protein fragments and can cause an immune response against the body’s own cells due to cross-reactivity.